XENETIC BIOSCIENCES, INC. Adjustments to Additional Paid in Capital, Other
XENETIC BIOSCIENCES, INC. (XBIO) reported Adjustments to Additional Paid in Capital, Other of $47.43 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-16.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2021-03-16
- XENETIC BIOSCIENCES, INC. adjustments to additional paid in capital, other for the quarter ending 2019-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. adjustments to additional paid in capital, other for the quarter ending 2019-09-30 was $15.00K, a 13.93% decline year-over-year.
- XENETIC BIOSCIENCES, INC. adjustments to additional paid in capital, other for the quarter ending 2019-06-30 was $15.00K, a 13.93% decline year-over-year.
- XENETIC BIOSCIENCES, INC. adjustments to additional paid in capital, other for the quarter ending 2019-03-31 was $17.43K, a 254.42% increase year-over-year.
- XENETIC BIOSCIENCES, INC. adjustments to additional paid in capital, other for fiscal 2019 was $47.43K.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 3 month as first filed | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $15.00K derived: sum of 2 quarters · filed 2021-03-16 | $30.00K derived: sum of 3 quarters · filed 2021-03-16 | $47.43K 10-K · filed 2021-03-16 | |
| 2019-09-30 | $15.00K 10-Q · filed 2020-11-12 | $30.00K derived: sum of 2 quarters · filed 2020-11-12 | $47.43K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $15.00K 10-Q · filed 2020-08-12 | $32.43K 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | $17.43K 10-Q · filed 2020-05-14 | -$26.58K 10-Q · filed 2019-05-13 | |||
| 2018-09-30 | $17.43K 10-Q · filed 2019-11-14 | $34.85K derived: sum of 2 quarters · filed 2019-11-14 | $52.28K 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $17.43K 10-Q · filed 2019-08-14 | $34.85K 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | $4.92K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |